ischemic stroke.
Conditions
Interventions
Intervention group: Participants receive Ticagrelor + Aspirin or Clopidogrel + Aspirin therapy for 21 days.Ticagrelor + Aspirin:Ticagrelor: 180 mg loading dose, then 90 mg every 12 hours.Aspirin: 325
Sponsors
Qazvin University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Signing the informed consent form to enter the study 2. Patients aged 40 or older 3. NIHSS score 0 to 4 (calculated based on the attached file)
Exclusion criteria
Exclusion criteria: 1. Patients with a history of AF (atrial fibrillation), ventricular aneurysm, and suspected cardioembolic origin for TIA or minor stroke, candidates for carotid surgery. 2. Presence of any problem that causes discontinuation of drug therapy for three days. 3. Presence of coagulation and bleeding disorders and history of non-traumatic intracerebral bleeding, gastrointestinal bleeding in the past 6 months 4. Major surgery in the past 30 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stroke recurrence rate (percentage of patients with recurrent ischemic stroke within 90 days)Mortality rate (percentage of deaths within the study period)Neurological recovery (NIHSS score improvement from baseline). Timepoint: Baseline (Before intervention)Day 21 (End of antiplatelet therapy)Day 90 (Final follow-up). Method of measurement: Stroke recurrence rate – Evaluated using clinical examination and brain imaging techniques at specified time points.Mortality rate – Determined through hospital records and follow-up assessments during the study period.Neurological recovery – Measured using the National Institutes of Health Stroke Scale (NIH Stroke Scale) through structured patient assessments. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Mahsa Moradnia
Qazvin University of Medical Sciences
Outcome results
None listed